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Abstract
Background: There is a need for greater understanding of the impact of multiple sclerosis (MS) from the
perspective of individuals with the condition. The South West Impact of MS Project (SWIMS) has been designed to
improve understanding of disease impact using a patient-centred approach. The purpose is to (1) develop
improved measurement instruments for clinical trials, (2) evaluate longitudinal performance of a variety of patient-
reported outcome measures, (3) develop prognostic predictors for use in individualising drug treatment for
patients, particularly early on in the disease course.
Methods: This is a patient-centred, prospective, longitudinal study of multiple sclerosis and clinically isolated
syndrome (CIS) in south west England. The study area comprises two counties with a population of approximately
1.7 million and an estimated 1,800 cases of MS. Self-completion questionnaires are administered to participants
every six months (for people with MS) or 12 months (CIS). Here we present descriptive statistics of the baseline
data provided by 967 participants with MS.
Results: Seventy-five percent of those approached consented to participate. The male:female ratio was 1.00:3.01 (n =
967). Average (standard deviation) age at time of entry to SWIMS was 51.6 (11.5) years (n = 961) and median
(interquartile range) time since first symptom was 13.3 (6.8 to 24.5) years (n = 934). Fatigue was the most commonly
reported symptom, with 80% of participants experiencing fatigue at baseline. Although medication use for symptom
control was common, there was little evidence of effectiveness, particularly for fatigue. Nineteen percent of participants
were unable to classify their subtype of MS. When patient-reported subtype was compared to neurologist assessment
for a sample of participants (n = 396), agreement in disease sub-type was achieved in 63% of cases. There were 836
relapses, reported by 931 participants, in the twelve months prior to baseline. Twenty-three percent of the relapsing-
remitting group and 12% of the total sample were receiving disease-modifying therapy at baseline.
Conclusions: Demographics of this sample were similar to published data for the UK. Overall, the results broadly
reflect clinical experience in confirming high symptom prevalence, with relatively little complete symptom relief.
Participants often had difficulty in defining MS relapses and their own MS type.
Background
The South-West Impact of Multiple Sclerosis study
(SWIMS) is a longitudinal cohort study from the per-
spective of people with MS. This paper outlines the
rationale, methods and baseline results from the
SWIMS cohort.
Multiple sclerosis (MS) is a complex and unpredict-
able disease with potential considerable impact on daily
living, both for people with the condition and their
carers. In order to develop and test new treatments in
the context of clinical trials, there is a need for greater
understanding of its impact, particularly from the
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people with MS have identified research into symptom
relief as a high priority, there are relatively few effective
symptomatic treatments, and many clinical trials of
symptomatic treatments have been disappointingly nega-
tive. One reason for this may be that current methods
for measuring disease impact are inadequate, and the
relationship between symptoms, impairment and disabil-
ity is not fully understood. In addition, measurement
instruments often demonstrate limitations. For example,
although fatigue is one of the most commonly reported
symptoms in people with MS, and there are several
scales purporting to measure the concept of fatigue, in
clinical studies results using different fatigue scales may
not strongly correlate with each other [1]. Given such
limitations of the available measurement instruments it
may not be surprising that few significant treatment
effects are identified in clinical trials.
When attempting to evaluate disease impact, changes
have generally been defined as objectively as possible,
usually from the perspective of the neurologist, using
clinical signs derived from neurological examination.
There are several problems associated with this
approach, including subjective interpretation of signs in
a complex condition, as well as difficulties in detecting
change over time. Another issue illustrating disease
complexity lies in the way in which relapses are mea-
sured. Most clinical trials define relapses in terms of
persistence of symptoms and signs, usually supported by
changes on neurological examination. Yet we know that
the frequency of changes on cranial magnetic resonance
imaging (MRI) greatly exceeds the number of relapses
supported by changes on neurological examination, and
patients often report greater variability in their condition
than can usually be confirmed by signs on neurological
examination [2,3]. There is very little available informa-
tion about relapses from the patient perspective, and
even less data on the reliability of such information.
In trying to measure the impact of MS, to understand
the natural history of MS, and establish the effectiveness
of disease-modifying treatments, scales such as the
Expanded Disability Status Scale (EDSS) [4] have
become established as the most widely used “objective”
means of measuring disease course. The EDSS is imple-
mented by neurologists and has many accepted limita-
tions, yet virtually all natural history studies have used
the EDSS. A lack of responsiveness, amongst other lim-
itations of the EDSS, means that clinical trials involving
progressive MS patients are usually three years in dura-
tion, which can lead to a risk of patient drop-out. This
may result in reduced statistical power to obtain an
answer to the research question, such as occurred in the
recent PrOMISe study [5]. In response to the recognised
limitations of the EDSS, other instruments such as the
MS Functional Composite [6] and the patient-reported
MS Impact Scale-29 [7] have been developed and
recommended for incorporation into clinical trials.
Responsive patient-orientated rating scales have the
potential to provide data which are sensitive to changes
in disease. Such scales could therefore be used to model
disease progression, in part to inform clinical trial meth-
odology and also to provide relevant prognostic infor-
mation for people early in the disease course. A more
refined approach to providing prognostic information,
from data derived over shorter periods, may enable
patients and health care professionals to make better-
informed decisions with regard to risk and benefit of
emerging treatments. However, there are very little long-
itudinal data available based on these newer instru-
ments, thus little data on which to model disease
progression and to use in performing power calculations
for clinical trials. Therefore there remains a need to
evaluate patient-reported rating scale performance over
time.
Although there have been studies evaluating preva-
lence of certain common symptoms such as pain, fatigue
and tremor, with limited investigation of longitudinal
change over time [8-10], there has been little systematic
evaluation of symptoms and how they change over time,
and few studies of the relationship between prevalent
symptoms and other aspects of disease impact. There
remains a need to understand the impact of symptoms
on disease progression.
SWIMS therefore has three major aims: 1) to facilitate
a better understanding of disease impact from the
patient perspective, in order to develop improved mea-
surement instruments for clinical trials and clinical
practice, 2) to evaluate longitudinal performance of a
variety of commonly used, patient-reported outcome
measures, 3) to collect, analyse, and model patient-
orientated longitudinal data in order to evaluate prog-
nostic predictors and facilitate more individualised treat-
ment in future patients, particularly early in the disease
course.
Here we present summaries of the baseline data pro-
vided by the first 967 participants to consent to
SWIMS.
Methods
Study Area
The SWIMS cohort is drawn from Devon and Cornwall
- two counties which form a sea-bordered peninsula in
south west England, covering 10,270 km
2 in area. The
study area is situated at latitude 50.78, longitude -3.00,
at the most easterly point and latitude 50.12, longitude
-5.53, at the most westerly point.
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[11] is served by five acute hospitals and three neurology
centres, each with its own rehabilitation centre. Devon
and Cornwall are ideally suited to this type of longitudi-
nal cohort study as the population is relatively stable
and migration rates are low[12,13].
In our prevalence study of MS in an area within the
study region, we found a rate of 118 per 100,000, in a
population of 341,796[5]. Based on this prevalence, we
estimate the number of cases of MS in the SWIMS
study region to be approximately 1,800[6].
Eligibility criteria
Inclusion criteria: clinical diagnosis of MS by either
McDonald or Poser criteria, or diagnosis of clinically
isolated syndrome (CIS), aged 18 years and over, and
resident in Devon or Cornwall. Exclusion criterion:
severe cognitive impairment such that the patient is
unable to provide informed consent.
Recruitment
The study was approved by the Cornwall and Plymouth
Research Ethics Committee and the South Devon
Research Ethics Committee, and adheres to the Data
Protection Act 1998. SWIMS commenced in August
2004, and continues to recruit new participants. Follow-
up is expected to continue until 2019.
Patients with established MS or CIS are invited to take
part by one of the following routes:
1) Patients attending neurology outpatient clinics are
approached by their neurology team.
2) Patients identified from review of hospital case
notes are approached by their neurologist.
3) A survey of General Practitioners within Devon and
Cornwall was conducted in which GPs were asked to
approach eligible patients known to them who had not
previously been approached by other routes.
4) Patient self-referral, in response to public aware-
ness campaigns involving the Multiple Sclerosis
Society and local media, or via information on the
SWIMS website.
Informed consent is obtained to retain the data pro-
vided and to review previous medical records in order
to verify diagnosis.
Data collection
Consented MS patients are asked to complete question-
naire booklets twice per year. The full details of the
questionnaire can be found at http://www.pms.ac.uk/
cnrg/swims, but briefly data collection includes: type of
MS (with examples of MS sub-types represented graphi-
cally in order to assist in classification, similar to Bamer
et al and Lublin and Reingold [14,15]), relapses, symp-
toms, medication, investigations, contact with health
and social care professionals, and whether the partici-
pant feels that he/she has deteriorated in the previous
six months. The questionnaire booklet contains the fol-
lowing definition of a relapse: “a worsening of existing
neurological symptoms which lasts for at least 48 hours,
or the appearance of a new neurological symptom
which lasts for at least 48 hours”. A range of validated
questionnaires is included (Table 1). In addition, the
Table 1 Validated instruments included in questionnaire booklets
MS Baseline
Questionnaire
MS 6-Monthly Follow-
Up Questionnaire
Version A*
MS 6-Monthly Follow-
Up Questionnaire
Version B*
CIS Baseline
Questionnaire
CIS 12-Monthly
Follow-Up
Questionnaire
EuroQol [27] ✓✓ ✓ ✓
Fatigue Severity Scale [28] ✓✓
Functional Assessment of MS
(modified 44-items scale) [29]
✓✓
General Health Questionnaire-30
[30]
✓✓ ✓ ✓
Medical Outcomes Study Short
Form 36-Item Health Study (version
2) [31]
✓✓ ✓ ✓
MS Disease Impact Scale-29
(version 2) [7]
✓✓
MS Neuropsychological Screening
Questionnaire [32]
✓✓
MS Walking Scale (version 2) [33] ✓✓
Postal Barthel Index [34] ✓✓
*To minimise the risk of overburdening participants, participants are randomly allocated to receive initially either Version A or Version B. Participants then receive
alternate versions every six months.
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onset of MS, e.g. date of diagnosis.
Consented CIS patients complete similar question-
naires once per year, with data collected on episodes of
inflammation, symptoms, treatments, investigations, con-
tact with health professionals and whether the diagnosis
of CIS has changed. Three validated questionnaires are
also included (Table 1). Patients with CIS at baseline who
are subsequently diagnosed with MS are switched to the
six-monthly MS data collection schedule.
In addition to the patient-completed questionnaires,
EDSS is assessed for patients attending neurology outpa-
tient clinics at one of the neurology centres, but no spe-
cific clinic attendance is organised to evaluate relapse
information. SWIMS is therefore very much patient-
orientated, complemented by information from neurolo-
gical appointments where available.
To examine the reliability of patient-reported MS sub-
type, we conducted a comparison of patient-reported
MS subtype with neurologist evaluation using retrospec-
tive case note evaluation. All participants were asked in
the baseline questionnaire to indicate which type of MS
they considered that they had. Case notes for the first
396 participants by surname were reviewed by the pro-
ject coordinator or neurologist for this purpose.
Data management
Anonymised data are input to a bespoke Microsoft SQL
S e r v e r2 0 0 5d a t a b a s e ,u s i n gad o u b l ed a t ae n t r ys y s t e m
to eliminate data entry errors. Data are then exported to
statistical packages including SPSS (version 15) and
Minitab (version 15) for summarizing and statistical
analysis.
Data analysis
Data from 967 baseline questionnaires completed by
participants with MS were collated and summarised
using descriptive statistics to provide a comprehensive
profile of this cohort.
Results and Discussion
Recruitment and follow-up
Figure 1 illustrates the disposition of MS patients
approached to participate between August 2004 and
A p r i l2 0 0 8a sw e l la sf o l l o w - u pr a t e sd u r i n gt h i st i m e
period. Within the same period, 40 invitations were sent
to patients with CIS, of whom 35 (87.5%) consented to
participate. Two participants with CIS were subse-
quently diagnosed with MS, and a further four partici-
pants with CIS were lost to follow-up (due to moving
outside the study area).
Approximately 75% of those provided with informa-
tion about the project between August 2004 and April
2008 consented to take part, which we consider to be a
reasonable recruitment rate for this type of study. How-
ever, it is still important to understand why people
chose not to take part. Reasons given to the neurologist
for not taking part included a preference not to be
reminded of the diagnosis of MS, particularly in the
early stages of the condition.
The predominant source of recruits (63% of those
recruited) was the consultant-led outpatient neurology
clinic. A further 21% had been approached following
review of the hospital notes, 10% were self-referrals, and
6% had been approached by their General Practitioner
on behalf of the research team.
Median duration of follow-up is 2.0 years (n = 1023),
with initial recruits to SWIMS having completed four
years of follow-up. Eighty-eight people (8% of those con-
sented) were lost to follow-up to the end of April 2008:
47 (4% of those consented) decided to withdraw, 25
(2%) died, 15 (1%) moved out of the study area, 1 (<
1%) had the diagnosis of MS revoked. The most com-
mon reasons for self-withdrawal were: “in poor health”
and “questionnaires too difficult/burdensome”.Q u e s -
tionnaire completion is consistently high, with 92% of
the 5075 booklets sent to participants up to the end of
April 2008 returned to the research team. The question-
naire return rates of around 90% are remarkable, and
are being maintained by providing regular newsletters
about the project and an appreciation by people with
MS that the information being collected will lead to
improved understanding and treatments in due course.
The large sample size also provides reassurance of lim-
ited potential bias. Participant retention in long-term
studies is a crucial issue when considering current
methods of testing treatments in progressive MS. We
are currently exploring methods of maximising retention
to SWIMS, including use of internet data capture and
on-line questionnaire completion.
Recruitment and data collection will continue for the
foreseeable future, and we expect the information
derived from this study to become increasingly useful
over time. Because the project is a longitudinal study of
patient-reported outcomes, we have excluded people
with severe cognitive impairment, as we do not have
validated methods for patient-reported data under these
circumstances. This may inevitably lead to a degree of
bias in the overall results in epidemiological terms, but
this design will be able to address the aims of the pro-
ject, namely to enable a better understanding of disease
impact, to evaluate and improve on patient-reported
outcomes, and to develop alternative prognostic models.
Baseline data for MS patients
Participant demographics
Seventy five percent of the study sample (n = 967) was
female, a ratio of 3.01:1.00. The age range at time of
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(standard deviation) of 51.6 (11.5) years (n = 961). Mean
(standard deviation) age at disease onset, i.e. patient-
reported date of first MS symptom, was 35.4 (10.8)
years (n = 902). The median (inter-quartile range) time
since first symptom of MS to time of entry to SWIMS
was 13.3 (6.8 to 24.5) years (n = 934) and median
(inter-quartile range) time since diagnosis was 9.9 (2.9
to 15.9) years (n = 921).
Diagnosis was reported to have been assisted using
MRI in 84% of the sample. Thirty-five percent of the
participants had MRI together with lumbar puncture
and evoked potentials, whereas 8% of participants had
been diagnosed on clinical grounds only. The demo-
graphics of the SWIMS sample were similar to other
surveys of MS in regions of the UK, as reviewed by Fox
et al [16].
Type of MS
Thirty six percent of participants reported that they had
relapsing-remitting MS (RRMS) at time of entry to
SWIMS, 21% had primary progressive MS (PPMS), 19%
had secondary progressive (SPMS), 3% had a benign
type and 21% did not know which type. When com-
pared to neurologist assignment of MS subtype, agree-
ment was achieved in 63% of the 396 cases reviewed.
Cohen’s kappa statistic was 0.48: a “moderate” level of
agreement according to Altman[17]. The 95% confi-
dence interval for kappa was 0.42 to 0.54.
The most common differences amongst the remaining
cases were (a) when the participant was unsure of MS
type and the neurologist was able to define subtype (n =
58, 15% of total), (b) where the participant felt they
were in the RR phase, but the neurologist felt they were
progressive (n = 31, 8%), (c) when there was disagree-
ment between PPMS and SPMS (n = 28, 7%). and (d)
when patients identified themselves as having progres-
sive disease, but the neurologist had assigned RRMS
(n = 12, 3%).
Defining MS subtypes can be an inexact science, even
from the perspective of the neurologist. For example, in
progressive disease, when an individual may present in
m i d d l ea g ew i t hah i s t o r yo fo n eo rm o r ep o s s i b l en e u -
rological events earlier in life, it can be difficult to define
subtype with certainty. Similarly, when an individual has
had a diagnosis of RRMS and starts to acquire increas-
ing disability, the precise definition of onset of second-
ary progression becomes blurred. Our experience is that
patients often have difficulty in defining their own dis-
ease course, and the current levels of uncertainty are
not unexpected.
Relapse data
Participants were asked to give details on any relapses
that they had had in the previous twelve months. The
number of relapses, by patient-reported MS type, is
summarised in Table 2. Overall, 36% of participants
were relapse-free in the previous twelve months. Across
all participants, the mean (standard deviation) number
of relapses was 0.9 (1.1) per year, whilst the mean (stan-
dard deviation) number of relapses in those reporting at
least one relapse in the previous twelve months was 1.8
(1.0) per year.
The use of steroids in association with relapses, time
off work due to relapses, hospitalisation and limitations
in everyday activities associated with relapses are sum-
marised in Table 3. Of all the 835 relapses in the pre-
vious twelve months, 157 (19%) resulted in no time off
work, 61 (7%) resulted in less than one week off work,
38 (5%) resulted in one to two weeks off work and 106
(18%) resulted in more than two weeks away from work.
For 394 relapse incidents (47%) the individual was not
Table 2 Patient-reported number of relapses in twelve
months prior to baseline: percentage of participants
experiencing relapse(s) by MS type
Number of relapses in last twelve
months
MS Type 0 1 2 3 4 Don’t know
Benign (n = 28) 54 39 0 0 0 7
Relapsing-Remitting (n = 345) 23 35 19 9 6 8
Primary Progressive (n = 182) 65 13 6 2 3 12
Secondary Progressive (n = 178) 33 34 9 7 3 14
Don’t Know (n = 173) 30 23 15 7 3 22
All (n = 931) 36 28 13 7 4 13
Data for MS subtype or the number of relapses or both were missing for 36
participants.
Table 3 Patient-reported impact of relapse(s) in twelve months prior to baseline: percentage of relapses by relapse
number
Relapse Number Oral
steroids
IV
steroids
Time off
work
Hospitalised Limitations to
everyday activities
1
st or only relapse (n = 477) 19 16 25 15 78
2
nd (n = 221) 14 11 24 7 76
3
rd (n = 99) 9 7 19 5 73
4
th (n = 38) 5 8 18 8 63
All relapses (n = 835) 16 13 24 11 76
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relapses (10%). In total, 2% of relapses were treated with
both oral and intravenous steroids, 12% with intrave-
nous steroids only and 14% were treated with oral ster-
oids only (at various doses).
Data on MS relapse can be notoriously difficult to
interpret, with the presence of daily symptom variation
and “pseudorelapse”, in which a variety of mechanisms
other than an increase in disease activity is responsible
for symptom deterioration. Although many clinical trials
have used the original Poser criterion [18] for relapse, of
at least twenty-four hours of neurological deterioration,
we opted for the more stringent definition of at least
forty-eight hours of change in symptoms. This more
stringent definition has previously been used in clinical
trials (for example in Jacobs et al [19]) and it was felt to
be more appropriate in the context of patient self-
report, in order to minimise the potential for reporting
of pseudorelapse.
Previous data on relapse frequency with retrospective
assessment in cross sectional studies provide a figure of
< 0.5/year, whereas prospective evaluation of relapses
provides a higher figure, of between 0.5 and 1.0 relapse/
year (reviewed in Confavreux and Compston[20]). Data
from the present SWIMS cohort would therefore be
consistent with other studies in which more formal eva-
luation of relapses has taken place, and suggests that
patient report could be a valid and less resource inten-
sive method for relapse assessment. Further work is
needed to investigate this assumption and also to evalu-
ate the impact of relapse on both overall disease course
and from the patient perspective.
Not unexpectedly, some patients who classified them-
selves as either PPMS or SPMS continued to report hav-
ing relapses, with the mean (standard deviation) relapse
frequency being higher in the SPMS group (0.8 (1.1) per
year) compared to the PPMS group (0.4 (0.9) per year).
This is consistent with other data from PPMS popula-
tions; a significant minority (28% in one study[21]) of
patients with PPMS reported an apparent relapse at
some time during the course of the disease[22].
Although around three quarters of relapses were asso-
ciated with limitation of everyday activities, only 11% of
relapses resulted in hospital admission, which is consis-
tent with an increasing tendency to use oral steroids
rather than intravenous steroids. Not surprisingly, con-
siderable time was lost off work due to relapse.
Although previous studies have considered employment,
e.g. Kobelt et al [23], very little work has been done on
the full economic impact of relapse when adjusted for
loss of earnings. The present SWIMS cohort sample is
likely to have less bias than some previous work in this
regard. For example, although Kobelt’s study [23]
included questionnaire data from over 13,000 people
with MS, administered through the national MS Society,
this represented a response rate of only 19%. The
SWIMS data provide some insight into relapse impact
in the era of disease modifying drugs, but much more
work is needed to develop rigorous ways of evaluating
relapse impact at all stages of the disease. The data
would suggest that there is a need to provide a better
definition of relapse from the patient perspective, with-
out resorting to the EDSS or neurological examination.
This may have implications for the use of disease modi-
fying treatments, and further work investigating the rela-
tionship between patient-identified relapse and long-
term disability would be useful.
Symptoms
Participants were asked to indicate their current symp-
toms, if any. Table 4 lists the percentages of all partici-
pants reporting symptoms at the time of completion of
the baseline questionnaire, by patient-reported MS type.
It is not surprising that fatigue was the most commonly
reported symptom across all participants. Regarding sub-
types of MS, sensory symptoms were slightly more com-
mon than fatigue in the benign disease subgroup, and in
both types of progressive disease (primary and secondary)
balance difficulties were slightly more common than fati-
gue. Memory problems were reported by about 60% of
patients, with the only major difference between subtypes
being that benign disease was associated with less mem-
ory trouble (35%). Similarly, concentration difficulties
were reported by around 50% of the participants, with
few differences between subtypes except benign MS
where the reported prevalence was 38%.
Medication
Participants were asked to indicate which medications
they were currently taking, or had taken in the last twelve
months. Of the total SWIMS participants (n = 967),
18.1% were currently taking or had previously taken
some form of disease modifying therapy (including beta-
interferon, glatiramer acetate, azathioprine, alemtuzemab,
mitoxantrone and cyclophosphamide). Within the RRMS
group 31% (n = 347) were currently receiving or had pre-
viously received disease modifying medication. The per-
centages currently on this type of medication were 23%
of the RR group and 12% of the total sample. The com-
monest disease modifying drugs in use were one of the
forms of beta-interferon and glatiramer acetate (22% of
RR group and 11% of the total sample).
In order to obtain a picture of the possibly unmet
need for symptom treatment in MS, we report symp-
toms and associated medication use in Table 5.
Although 769 patients (80% of the cohort) experienced
fatigue, only 3 people were taking amantadine or moda-
fanil and were without fatigue. Fifty people (7%) were
taking one of these medicines and continued to have
fatigue. Among the large percentage of people with
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associated oral medication. Five percent of people with
bladder symptoms had obtained complete symptom
relief, as indicated by the number of participants with-
out current symptoms of bladder dysfunction but
currently taking medication indicated for bladder
dysfunction.
Over 70% of the SWIMS cohort experience pain of
some type, most commonly treated with paracetamol or
ibuprofen, both available without prescription in the
Table 4 Symptoms reported at baseline: percentage of participants by self-reported MS type
All
(n = 967)
Benign
(n = 29)
Relapsing-remitting
(n = 347)
Primary progressive
(n = 202)
Secondary progressive
(n = 184)
Fatigue 80 38 80 83 83
Poor balance 75 35 64 90 89
Any pain, including visual pain 70 35 67 77 76
Any pain (not visual) 69 35 65 76 75
Muscle weakness 64 28 53 82 80
Problems with memory 57 35 58 57 59
Pins and needles/tingling 56 45 59 54 55
Decreased or worsening mobility 56 10 35 81 76
Muscle stiffness 54 21 48 64 67
Muscle spasms 53 17 44 66 67
Sensory loss/numbness 53 28 53 49 65
Loss of dexterity 52 21 41 65 70
Urinary urgency 49 38 44 49 57
Muscular pain 49 28 42 57 57
Problems with concentration 49 38 50 47 54
Urinary frequency 48 38 45 52 53
Constipation 44 28 40 48 52
Difficulties with co-ordination 43 14 33 56 56
Emotional lability 42 28 46 38 39
Joint pain 40 21 36 45 42
Feeling anxious 35 31 31 39 39
Urinary incontinence 30 24 19 39 41
Depression 30 21 28 31 30
Urinary hesitancy 29 14 24 31 39
Weight gain 28 10 23 33 32
Blurred vision 27 14 29 25 28
Sexual problems 27 14 23 29 36
Tremor 26 7 19 35 33
Burning pain 25 21 23 24 29
Shooting pain 23 10 21 23 26
Swallowing difficulties 21 7 13 27 28
Speech problems 21 7 16 26 25
Faecal incontinence 13 7 8 15 22
Other pain 13 10 12 13 14
Double vision 12 10 10 15 17
Weight loss 10 14 6 10 16
Diarrhoea 10 10 9 8 9
Painful vision 9 4 10 8 12
Colour desaturation 8 4 10 5 7
Pressure sores 4 0 2 8 6
A total of 205 participants did not know their MS type, or did not report an MS type.
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Symptom Number (%) of
participants
with current symptom
Associated
medication
Number (%) of participants
with current symptom
Number (%) of
participants
without current
symptom
currently taking
associated
medication
not currently
taking,
but previously
taken,
associated
medication
currently taking
associated medication
Fatigue 769 (80) Amantadine 33 (4) 35 (5) 2 (1)
Modafinil 17 (2) 16 (2) 1 (1)
Bladder 756 (78) Desmopressin spray 6 (1) 9 (1) 0
Desmopressin
tablets
5 (1) 3 (0) 0
Oxybutinin 93 (12) 64 (8) 6 (3)
Tolterodine 63 (8) 25 (3) 2 (1)
Trimethoprim 27 (4) 35 (5) 2 (1)
Pain (including visual
pain)
681 (71) Amitriptyline 123 (18) 85 (12) 19 (7)
Carbemazepine 39 (6) 47 (7) 4 (1)
Co-codamol 107 (16) 117 (17) 8 (3)
Gabapentin 83 (12) 48 (7) 5 (2)
Ibruprofen 127 (19) 194 (28) 28 (10)
Nabilone 6 (1) 7 (1) 0
Paracetamol 188 (28) 193 (28) 28 (10)
Spasticity 672 (70) Baclofen pump 6 (1) 1 (0) 2 (1)
Baclofen tablets 163 (24) 78 (12) 17 (6)
Botulinum toxin 2 (< 1) 0 (0) 0
Clonazepam 24 (4) 9 (1) 2 (1)
Dantrolene 7 (1) 5 (1) 1 (< 1)
Diazepam 26 (4) 64 (10) 4 (1)
Tizanidine 45 (7) 16 (2) 2 (1)
Pain (excluding visual
pain)
670 (69) Amitriptyline 123 (18) 86 (13) 19 (6)
Carbemazepine 39 (6) 47 (7) 4 (1)
Co-codamol 104 (16) 117 (17) 11 (4)
Gabapentin 82 (12) 48 (7) 6 (2)
Ibruprofen 126 (19) 189 (28) 29 (10)
Nabilone 6 (1) 6 (1) 0
Paracetamol 185 (28) 192 (29) 31 (11)
Depression 484 (50) Citalopram 34 (7) 15 (3) 3 (1)
Fluoxetine 47 (10) 33 (7) 14 (3)
Paroxetine 9 (2) 12 (3) 7 (2)
Sertraline 13 (3) 3 (1) 3 (1)
Constipation 421 (44) Fybogel 32 (8) 76 (18) 8 (2)
Senna 65 (15) 98 (23) 7 (1)
Sexual problems 256 (27) Viagra 34 (13) 16 (6) 9 (1)
Sexual problems (males
only)
129 (54
1) Viagra 34 (26) 15 (12) 9 (1)
Tremor 248 (26) Propranolol 10 (4) 7 (3) 5 (1)
1 54% of males in study sample.
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Page 9 of 11UK. About 10% of the cohort who did not report having
pain, continue to take such simple analgesics.
Symptoms of spasticity were also present in around
70% of the cohort, and about one third of people
affected were taking some medication for this, with sin-
gle figure percentages obtaining complete symptom
relief (using the assumption given above for bladder
dysfunction).
Contact with health and social care specialists
Participants were asked to indicate whether they had
seen any specialists about their MS in the last twelve
months and if so, how often (Table 6). Access to specia-
list services will vary both within and between counties.
Asking about service contact, relapses and symptoms
enables a broad picture to be created of the impact of
MS on individuals and the ability of health services to
deal with that impact. Considerable service demands are
placed on primary care, even though each General Prac-
titioner may only expect to have two to four patients
with MS on their list. This is evident even when specia-
list nurses and neurologists with an interest in MS are
available. At the other end of the scale, considering the
prevalence of cognitive symptoms and pain, contact
with clinical psychology and the pain management ser-
vices is surprisingly low. It is difficult to know whether
this reflects poor availability of services or problems in
care pathways. Although there are some recommenda-
tions concerning the ratio of specialist nurses to popula-
tion, there is comparatively little available data on case-
mix for individual health specialists, making health plan-
ning difficult. Once again, there is a need for more work
on the comparative success of treatments and support
made available by each of the range of individuals that
comprises the multidisciplinary team.
Conclusions
Here we describe the rationale for SWIMS and report
t h eb a s e l i n ec h a r a c t e r i s t i c so fac o h o r to f9 6 7p e o p l e
with MS. Overall, the data broadly reflect clinical experi-
ence in confirming high symptom prevalence with rela-
tively little complete symptom relief. Establishing
effective treatments for these symptoms must start with
a full appreciation of all aspects of symptom impact.
SWIMS is enabling new scales to be developed (e.g.
the MS Spasticity Scale, MSSS-88 [24]), and the perfor-
mance of other scales to be evaluated (including the
Fatigue Severity Scale [25], the General Health Ques-
tionnaire-30 [26], and the MS Walking Scale). Further
qualitative work will be necessary in order to inform
aspects of symptom impact useful for the creation of
new measurement instruments.
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